Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Oct;90(4):717-22.
doi: 10.1016/j.pbb.2008.05.018.

Modafinil decreases food intake in humans subjected to simulated shift work

Affiliations

Modafinil decreases food intake in humans subjected to simulated shift work

Gydmer A Perez et al. Pharmacol Biochem Behav. 2008 Oct.

Abstract

In a limited number of studies modafinil has been shown to decrease food intake by laboratory animals and humans. The present study represents a secondary data analysis, in which the effects of modafinil on several measures of food intake were determined in humans living in a residential laboratory during simulated shift work. During this 23-day study, a wide selection of food items and beverages were freely available. During this double-blind, within-participant study, volunteers (N = 11) received oral modafinil dose (0, 200, or 400 mg) 1 h after waking for three consecutive days under two shift conditions: day shift and night shift. Shifts alternated three times during the study, and shift conditions were separated by an "off" day. Modafinil (200, 400 mg) dose-dependently decreased total caloric intake by approximately 18% and approximately 38%, respectively, regardless of shift condition, without selectively altering the proportion of total calories derived from carbohydrate, fat and protein. Ratings of "Hungry" were also significantly decreased by both active doses, but only immediately before the lunch break period. In addition, tolerance to the anorexic effects of modafinil was not apparent, as these effects remained stable across the three days of modafinil dosing. These findings show that modafinil produced clear reductions in food intake and suggest that future prospective studies should examine the drug in obese participants.

PubMed Disclaimer

Conflict of interest statement

Disclosure/Conflict of interest: The authors declare, that except for income received from our primary employer, no financial support or compensation has been received from any individual or corporate entity over the past three years for research or professional service and there are no personal financial holdings that could be perceived as constituting a potential conflict of interest.

Figures

Figure 1
Figure 1
Upper Panels: Total kilocalories consumed as a function of modafinil dose (placebo, 200, 400-mg) and day within condition. Lower Panels: Number of eating occasions as a function of modafinil dose (placebo, 200, 400-mg) and day within condition. Left panels display results from the day shift and the right panels from the night shift. Error bars represent one SEM. An * indicates significantly different from placebo (p < 0.05). An § indicates significantly different from 200 mg (p < 0.05).
Figure 2
Figure 2
Grams of carbohydrate (upper panels) and fat (lower panels) intake as a function of modafinil dose (placebo, 200, 400-mg) and day within condition. Left panels display results from the day shift and the right panels from the night shift. Error bars represent one SEM. An * indicates significantly different from placebo (p < 0.05). An § indicates significantly different from 200 mg (p < 0.05).

Similar articles

Cited by

References

    1. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR. Gut hormone PYY(3–36) physiologically inhibits food intake. Nature. 2002;418(6898):650–654. - PubMed
    1. Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ, Jiang J, Greenhill L. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics. 2005;116(6):e777–784. - PubMed
    1. Boellner SW, Earl CQ, Arora S. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study. Curr Med Res Opin. 2006;22(12):2457–2465. - PubMed
    1. Boutrel B, Koob GF. What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep. 2004;27(6):1181–1194. - PubMed
    1. Broughton RJ, Fleming JA, George CF, Hill JD, Kryger MH, Moldofsky H, Montplaisir JY, Morehouse RL, Moscovitch A, Murphy WF. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 1997;49(2):444–451. - PubMed

Publication types